SFB 824 Subproject    (Nr.)     B04


1. General Information

Name:                            Gabriele Multhoff Dr. rer. nat.

Date/place of birth:          12.01.1961/Munich

Gender:                          female

Address of institution:      Klinikum rechts der Isar der TU München

                                      TranslaTUM, Radiation Immuno Oncology

                                      Einsteinstraße 25, 81675 München, Germany

Phone:                            +49 (0)89 4140 4514

E-mail:                            gabriele.multhoff@tum.de


Current Positions            Univ. Prof.

2. University education/ Degree(s)

1987 – 1991            PhD / Biochemical and cellular characterization of cytotoxic T cells recognizing self-MHC associated antigens as well as distinct allo-antigens / Institute of Immunology, Ludwig-Maximilians University / Munich

1982 - 1987             Student job / Mixed Lymphocyte Cultures (MLC) of leukaemic patients and their families / Institute of Immunology, Ludwig-Maximilians Universität / Munich

1980 – 1987            Biology Diploma / Ludwig-Maximilians University / Munich


3. Scientific degrees / Board certification

1991 - 1998             Habilitation / Characterization of therapy-induced modulations on tumor and immunocompetent effector cells: an in vitro model to develop an adjuvant immunotherapy for tumor patients Möllemann Habilitation Stipend) / LMU Munich / (Prof. W. Wilmanns)

4. Other scientific Degree

2006 - 2008             President “Cell Stress Society international, CSSI” / Connecticut, USA

Since 2003             Consultant Immunologist /LMU Munich

5. Professional Development (post university degree)

Since 2007                   Professorship for Radiooncology/Radiobiology: Technische Universität München, Klinikum rechts der Isar, Munich and Head of Clinical Cooperation Group “Innate Immunity in Tumor Biology“, Helmholtz Zentrum München, German Research Center of Environmental Health, Munich

2002 - 2007                  University Professor of Molecular Oncology at the University Hospital Regensburg

2002                            Professorships (2):

        • University Hospital Charité, Berlin (Tumors and Tumor Metastases)
        • University Hospital Regensburg, Germany (Molecular Oncology)

1998 - 2002                  Senior Scientist, ‘NK cells in Immunotherapy’ Research Group, University Hospital Regensburg, Germany

1999                            Founder of multimmune GmbH, Munich, Germany (CEO/CSO) – currently CSO, Munich

1990 - 1998                  Senior Scientist at the University Hospital Großhadern, Med. Klinik III, Ludwig-Maximilians University, Munich and GSF - National Research Center for Environment and Health Munich (CCG Hyperthermie)

6. Miscellaneous (Honors, Awards, Others)

2018        Peter Vaupel Award from the International Society on Oxygen Transport to Tissue (ISOTT)

2015        CESAR-Award (Central European Society for Anticancer Drug Research)

2012        Prof. Milton Yatwin Award, 7th Biennal Conference of IAHOM

1998        Paula and Richard von Hertwig Award, GSF Helmholtzgemeinschaft

1996        European Society of Hyperthermic Oncology Award, ESHO-BSD

1996        Young Investigator Award at the VII International Congress on Hyperthermic Oncology, ICHO

Since 2016       Editor, European Journal of Cell Biology

Since 2015       Editor, Molecular Immunology

Since 2015       Editor, Radiation Oncology

Since 2015       Editor, Annals of Hematology & Oncology

Since 2014       Wissenschaftlicher Beirat Springer Verlag Zeitschrift Strahlentherapie und Onkologie

Since 2014       Editor, World Cancer Research Journal

Since 2013       Editor, Molecular & Cellular Oncology

Since 2012       Editor, ISRN Biochemistry

Since 2012       Editor, Frontiers in Immunology

Since 2010       Editor, PLoS ONE

Since 2010       Editor, American Journal of Translational Research

Since 2010       Reviewer DFG - Deutsche Forschungsgemeinschaft (German Research Foundation)

2006                 Book Editor “Heat Shock Proteins in Biology and Medicine

Since 2005       European Editor, Cell Stress & Chaperones

7. Scientific Cooperations to close researchers within SFB 824 / external

V. Ntziachristos

C. Spitzweg

K. Steiger

JT Siveke

A. Krackhardt

C. DÁlessandria

RM Huber, LMU

F. Pfeiffer, TUM

D. Vodermark, Halle

F. Rödel, Frankfurt

U. Gaipl, Erlangen

AG Pockley, Nottingham, UK

G. Eissner, Dublin, Ireland

L. Vigh, Budapest, Hungary

B. Margulis, St. Petersburg, Russia

N. Murakami, Toyo, Japan

8. Publications

  1. Gehrmann M, Schilling D, Molls M, Multhoff G. Radiation induced stress proteins. Int J Clin Pharmacol Ther 48(7): 492-493, 2010.
  2. Riederer I, Sievert W, Eissner G, Multhoff G: Irradiation-induced differential expression of HLA-E affects lytic activity of NK cells. Plos One 5(12): e15339, 2010.
  3. Multhoff G, Hightower LE: Distinguishing integral and receptor-bound heat shock protein 70 (Hsp70) on the cell surface by Hsp70 specific antibodies. Cell Stress Chaperones 16(3): 251-255, 2011.
  4. Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G: Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. PNAS 108(2): 733-738, 2011.
  5. Stangl S, Gehrmann M, Dressel R, Alves F, Dullin C, Themelis G, Ntziachristos V, Staeblein E, Walch A, Winkelmann I, Multhoff G. In vivo imaging of CT26 mouse tumors by using cmHsp70.1 monoclonal antibody. J Cell Mol Med 15(4): 874-887, 2011.
  6. Chaachouay H, Ohneseit P, Toulany M, Kehlbach R, Multhoff G, Rodemann HP: Autophagy contributes to resistance profile of tumor cells to ionising radiation. Radiother Oncol 99(3): 287-292, 2011.
  7. Gehrmann M, Doss BT, Wagner M, Zettlitz KA, Kontermann RE, Foulds G, Pockley AG, Multhoff G. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J Immunol Methods 371: 8-17, 2011.
  8. Stangl S, Themelis G, Friedrich L, Ntziachristos V, Sarantopoulos A, Molls M, Skerra A, Multhoff G. Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment. Radiother Oncol 99: 313-316, 2011.
  9. Zlobinskaya O, Dollinger G, Michalski D, Hable V, Greubel C, Du G, Multhoff G, Roper B, Molls M, Schmid TE. Induction and repair of DNA double-strand breaks assessed by gamma-H2AX foci after irradiation with pulsed or continuous proton beams. Radiat Environ Biophys  1: 23-32, 2012.
  10. Schilling D, Bayer C, Emmerich K, Molls M, Vaupel P, Huber RM, Multhoff G. Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines. Strahlenther Onkol 188(4): 353-358, 2012.
  11. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol 2: 98, 2012.
  12. Schmid TE, Multhoff G. Radiation-Induced Stress Proteins – the Role of Heat Shock Proteins (HSP) in Anti-Tumor Responses. Curr Med Chem 19(12): 1765-1770, 2012.
  13. Schilling D, Bayer C, Li W, Molls M, Vaupel P, Multhoff G. Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1α. PlosOne 7(2): e31110, 2012.
  14. Multhoff G, Pockley AG, Streffer C, Gaipl US. Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity. Curr Mol Med 12: 1174-1182, 2012.
  15. Schmid TE, Multhoff G. Non-targeted effects of photon and particle irradiation and the interaction with the immune system. Front Oncol 2:80, 2012.
  16. Gehrmann M, Stangl S, Kirschner A, Foulds GA, Sievert W, Doß BT, Walch A, Pockley AG, Multhoff G. Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B. PlosOne 7(7): e41341, 2012.
  17. Foulds GA, Radons J, Kreuzer M, Multhoff G, Pockley AG. Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Front Oncol 14(3): 1-14, 2013.
  18. Schilling D, Düwel M, Molls M, Multhoff G. Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels. Cell Stress Chaperones 18(2): 183-191, 2013.
  19. Tapfer A, Bech M, Zanette I, Symvoulidis P, Stangl S, Multhoff G, Molls M, Ntziachristos V, Pfeiffer F. Three-dimensional imaging of whole mouse models: comparing nondestructive X-ray phase contrast micro-CT with cryotome-based planar epi-illumination imaging. J Microsc 253(1): 24-30, 2013.
  20. Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G. Validation of Heat Shock Protein 70 as a Tumor-Specific Biomarker for Monitoring the Outcome of Radiation Therapy in Tumor Mouse Models. Int J of Rad Oncol 88(3): 694-700, 2014.
  21. Multhoff G, Radons J, Vaupel P. Critical Role of Aberrant Angiogenesis in the Development of Tumor Hypoxia and Associated Radioresistance. Cancers 6: 813-828, 2014.
  22. Gaipl US, Multhoff G, Scheithauer H, Lauber K, Hehlgans S, Frey B, Rödel F. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunoth 6(5): 597-610, 2014.
  23. Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, Breuninger S, Hube K, Lehnerer S, Van Phi V, Sage E, Schmid TE, Sedelmayr M, Schilling D, Sievert W, Stangl S, Multhoff G. Hsp70 – a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Rad Oncol 9: 131, 2014.
  24. Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, Specht HM, Multhoff G. Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Front Immunol 5: 307, 2014.
  25. Gehrmann M, Stangl S, Foulds GA, Oellinger R, Breuninger S, Rad R, Pockley AG, Multhoff G. Tumor Imaging and Targeting Potential of an Hsp70-Derived 14-Mer Peptide. PlosOne 9(8): e105344, 2014.
  26. Stangl S, Varga J, Freysoldt B, Trajkovic-Arsic M, Siveke JT, Greten FR, Ntziachristos V, Multhoff G. Selective in vivo Imaging of syngeneic, spontaneous and xenograft tumors using a novel tumor cell-specific Hsp70 peptide-based probe. Cancer Res 74(23): 6903-6912, 2014.
  27. Pockley AG, Henderson B, Multhoff G. Extracellular cell stress proteins as biomarkers of human disease. Biochem Soc Trans 42(6): 1744-1751, 2014.
  28. Breuninger S, Erl J, Knape C, Gunther S, Regel Y, Rödel F, Gaipl US, Thorsteinsdottir J, Giannitrapani L, Dickinson AM, Multhoff G. Quantitative analysis of liposomal Heat Shock Protein 70 (Hsp70) in the blood of tumor patients using a novel LipHsp70 ELISA. Clin Cellular Immunol 5: 5, 2015.
  29. Azimzadeh O, Sievert W, Sarioglu H, Merl-Pham J, Yentrapalli R, Bakshi MV, Janik D, Ueffing M, Atkinson MJ, Multhoff G, Tapio S. Integrative Proteomics and Targeted Transcriptomics Analyses in Cardiac Endothelial Cells Unravel Mechanisms of Long-Term Radiation Induced Vascular Dysfunction. J Proteom Res 14: 1203-1219, 2015.
  30. Rödel F, Frey B, Multhoff G, Gaipl U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 356: 105-113, 2015.
  31. Schilling D, Kühnel A, Konrad S, Tetzlaff F, Bayer C, Yaglom J, Multhoff G. Sensitizing tumor cells to radiation by targeting the heat shock response. Cancer Lett 360(2): 294-301, 2015.
  32. Schilling D, Tetzlaff F, Konrad S, Li W, Multhoff G. A hypoxia-induced decrease of either MICA/B or Hsp70 on the membrane of tumor cells mediates immune escape from NK cells. Cell Stress Chaperones (1)20: 139-147, 2015.
  33. Multhoff G, Pockley AG, Schmid TE, Schilling D. The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett 368(2): 179-184, 2015.
  34. Schilling D, Kühnel A, Tetzlaff F, Konrad S, Multhoff G. NZ28-induced inhibition of HSF1, SP1 und NF-kB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells. Cancer Immunol Immunother  64: 599-608, 2015.
  35. Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G. Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) – from preclinical studies to a clinical phase II trial. Front Immunol 6: 162, 2015.
  36. Giannitrapani L, Multhoff G. The Role of HSP70 in the Diagnosis of HCC. Forum on Immunopathol Diseases Therapeutics 5(3-4): 137-143, 2014.
  37. Murakami N, Kühnel A, Schmid TE, Ilicic K, Stangl S, Braun IS, Gehrmann M, Molls M, Itami J, Multhoff G. Role of membrane Hsp70 in radiation sensitivity of tumor cells. Radiat Oncol 10: 149, 2015.
  38. Sievert W, Trott KR, Azimzadeh O, Tapio S, Zitzelsberger H, Multhoff G. Late proliferating and inflammatory effects on murine microvascular heart and lung endothelial cells after irradiation. Radiother Oncol 117(2): 376-381, 2015.
  39. Schwarzer J, Multhoff G. Commentary to: ‘A comparison of two commercially available ELISA methods for the quantification of human plasma heat shock protein 70 during rest and exercise stress’ by Lee et al. 2015. Cell Stress Chaperones 20(6): 865-866, 2015.
  40. Schmid TE, Friedland W, Greubel C, Girst S, Reindl J, Siebenwirth C, Ilicic K, Schmid E, Multhoff G, Schmitt, E, Kundrát, Dollinger G. Sub-micrometer 20 MeV protons or 45 MeV lithium spot irradiation enhances yields of dicentric chromosomes due to clustering of DNA double-strand breaks. Mutat Res Genet Toxicol Environ Mutagen 793: 30-40, 2015.
  41. Gehrmann MK, Kimm MA, Stangl S, Schmid TE, Noël PB, Rummeny E, Multhoff G. Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjuigated gold nanoparticles. Int J Nanomedicine 10: 5687-5700, 2015.
  42. Chaachouay H, Fehrenbacher B, Toulany M, Schaller M, Multhoff G, Rodemann HP. AMPK-independent autophagy promotes radioresistance of human tumor cells under clinical relevant hypoxia in vitro. Radiother Oncol 116(3): 409-416, 2015.
  43. Pockley AG, Foulds GA, Oughton JA, Kerkvliet NI, Multhoff G. Immune cell phenotyping using flow cytometry. Curr Protoc Toxicol 66:18.8.1-18.8.34. doi: 10.1002/0471140856.tx1808s66, 2015.
  44. Shevtsov MA, Nikolaev BP, Yakovleva LY, Parr MA, Marchenko YY, Eliseev I, Dobrodumov AV, Zlobina O, Zhakhov A, Ischenko AM, Pitkin E, Multhoff G. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. J Control Release 220: 329-340, 2015.
  45. Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G. Correlation of Hsp70 levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer. Front Immunol 6: 556, 2015.
  46. Shevtsov MA, Nikolaev BP, Ryzhov VA, Yakovleva LY, Marchenko YY, Parr MA, Rolich VI, Mikhrina AL, Dobrodumov AV, Pitkin E, Multhoff G. Ionizing radiation improves glioma-specific targeting of superparamagnetic iron oxide nanoparticles conjugated with cmHsp70.1 monoclonal antibodies (SPION-cmHsp70.1). Nanoscale 7: 20652-20664, 2015.
  47. Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE, Multhoff G. Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. Radiother Oncol 118(1): 176-180, 2015.
  48. Isernhagen A, Schilling D, Monecke S, Shah P, Elsner L, Walter L, Multhoff G, Dressel R. The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA. Immunogenetics 68(2): 109-123, 2016.
  49. Combs SE, Schmid TE, Vaupel P, Multhoff G. Stress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) Concepts. Cancers 8(1): E15, 2016.
  50. Vaupel P, Multhoff G. Adenosine can thwart antitumor responses elicited by radiotherapy. Strahlenther Onkol 192(5): 279-287, 2016.
  51. Multhoff G, Habl G, Combs SE. Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging. Int J Hyperthermia 32(4): 455-463, 2016.
  52. Shevtsov M, Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol 7: 171, 2016.
  53. Tzoumas S, Nunes A, Olefir I, Stangl S, Symvoulidis P, Glasl S, Bayer C, Multhoff G, Ntziachristos V. Eigenspectra optoacustic tomography achieves quantitative blood oxygenation imaging deep in tissues. Nat Commun 7: 12121, 2016.
  54. Shevtsov MA, Parr MA, Ryzhof VA, Zemtsova EG, Arbenin AY, Ponomareva AN, Smirnov VM, Multhoff G. Zero-valent Fe confined mesoporous silica nanocarriers (Fe(0)@ MCM-41)for targeting experimental orthotopic glioma in rats. Sci Rep 6: 29247, 2016.
  55. Shevtsov M, Multhoff G. Immunological and translational aspects of NK cell-based antitumor immunotherapies. Front Immunol 7: 492, 2016.
  56. Juric MK, Shevtsov M, Mozes P, Ogonek J, Crossland RE, Dickinson AM, Greinix HT, Holler E, Weissinger EM, Multhoff G. B-cell-based and soluble biomarkers in body liquids for prediting acute/chronic Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation. Front Immunol 7: 660, 2017.
  57. Shevtsov M, Huile G, Multhoff G. Membrane heat shock protein 70: a theranostic target for cancer therapy. Phil Trans R Soc B 373: 20160526, 2017.
  58. Sage EK, Schmid TE, Geinitz H, Gehrmann M, Sedelmayr M, Duma MN, Combs SE, Multhoff G. Effects of local radiotherapy on the composition of lymphocyte subpopulations in prostate and breast cancer patients. Strahlenther Onkol 193(8): 648-655, doi: 10.1007/s00066-017-1144-7, 2017.
  59. Thorsteinsdottir J, Stangl S, Fu P, Guo K, Albrecht V, Eigenbrod S, Erl J, Gehrmann M, Tonn JC, Multhoff G, Schichor C. Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas. J Neurooncol,  135(3): 443-452, doi: 10.1007/s11060-017-2600-z, 2017.
  60. Ostheimer C, Gunther S, Bache M, Vordermark D, Multhoff G. Dynamics of heat shock protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin. Front Immunol 18(8): 1305, doi: 10.3389/fimmu.2017.01305, 2017.
  61. Fang HY, Münch NS, Schottelius M, Ingermann J, Liu H, Schauer M, Stangl S, Multhoff G, Steiger K, Gerngroß C, Jesinghaus M, Weichert W, Kühl AA, Sepulveda AR, Wester HJ, Wang TC, Quante M. CXCR4 is a potential target for diagnostic PET/CT imaging in Barrett's dysplasia and esophageal adenocarcinoma. Clin Cancer Res 24(5): 1048-1061, doi: 10.1158/1078-0432.CCR-17-1756, 2018.
  62. Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Schmid TE, Pigorsch S, Combs SE, Haller B, Balermpas P, Rödel F, Rödel C, Fokas E, Krause M, Linge A, Lohhaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Maihöfer C, Mönnich D, Zips D, Multhoff G. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 142(9): 1911-1925, doi: 10.1002/ijc.31213, 2018.
  63. Shevtsov M, Nikolaev B, Marchenko Y, Yakovleva L, Skvortsov N, Mazur A, Tolstoy P, Ryzhov V, Multhoff G. Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs). Int J Nanomedicine 13: 1471-1482. doi: 10.2147/IJN.S152461, 2018.
  64. Sievert W, Stangl S, Steiger K, Multhoff G. Improved overall survival of mice by reducing lung side effects high-precision heart irradiation using a small animal radiation research platform. Int J Radiat Oncol Biol Phys 101(3): 671-679, doi: 10.1016/j.ijrobp.2018.02.017, 2018.
  65. Schug C, Sievert W, Urnauer S, Müller AM, Schmohl KA, Wechselberger A, Schwenk N, Lauber K, Schwaiger M, Multhoff G, Wagner E, Nelson PJ, Spitzweg C. External beam radiation therapy enhances mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Hum Gene Ther 29(11): 1287-1300, doi: 10.1089/hum.2018.025, 2018.
  66. Lechner P, Buck D, Sick L, Hemmer B, Multhoff G. Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. Mult Scler J Exp Transl Clin 4(2): 2055217318767192. doi: 10.1177/2055217318767192, 2018.
  67. Stangl S, Tei L, De Rose F, Reder S, Martinelli J, Sievert W, Shevtsov M, Öllinger R, Rad R, Schwaiger M, D`Alessandria C, Multhoff G. Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[89Zr] for tumor-specific PET/CT imaging. Cancer Res 78(21): 6268-628, doi: 10.1158/0008-5472.CAN-18-0707, 2018.
  68. Breuninger S, Stangl S, Werner C, Sievert W, Lobinger D, Foulds GA, Wagner S, Pickhard A, Piontek G, Kokowski K, Pockley AG, Multhoff G. Membrane Hsp70 – A novel target for the isolation of circulating tumor cells after epithelial-to-mesenchymal transition. Front Oncol 8: 497, doi: https://doi.org/10.3389/fonc.2018.00497, 2018.
  69. Reindl J, Shevtsov M, Dollinger G, Stangl S, Multhoff G. Membrane Hsp70-supported cell-to-cell connections via tunneling nanotubes revealed by live-cell STED nanoscopy. Cell Stress Chaperones 24(1): 213-221, doi: 10.1007/s12192-018-00958-w, 2019.
  70. Balogi Z, Multhoff G, Jensen TK, Lloyd-Evans E, Yamashima T, Jäättelä M, Harwood JL, Vígh L. Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. Prog Lipid Res 74: 18-30, doi: 10.1016/j.plipres.2019.01.004, 2019.
  71. Kokowski K, Stangl S, Seier S, Hildebrandt M, Vaupel P, Multhoff G. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. Strahlenther Onkol 195(4): 352-361, https://doi.org/10.1007/s00066-019-01434-9, 2019.
  72. Shevtsov M, Stangl S, Nikolaev B, Yakovleva L, Marchenko Y, Tagaeva R, Sievert W, Pitkin E, Mazur A, Tolstoy P, Galibin O, Ryzhov V, Steiger K, Smirnov O, Khachatryan W, Chester K, Multhoff G. Granzyme B functionalized nanoparticles targeting membrane Hsp70-positive tumors for multimodal cancer theranostics. Small 15(13): e1900205, doi: 10.1002/smll.201900205, 2019.
  73. Shevtsov M, Pitkin E, Ischenko A, Stangl S, Khachatryan W, Galibin O, Edmond S, Lobinger D, Multhoff G. Ex vivo Hsp70-Activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Front Immunol 10: 454, doi: 10.3389/fimmu.2019.00454, 2019.
  74. Rothammer A, Sage EK, Werner C, Combs SE, Multhoff G. Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy – after potential markers for predicting breast cancer recurrence? Radiat Oncol 14(1): 78, doi: 10.1186/s13014-019-1286-0, 2019.
  75. Salvermoser L, Dressel S, Schleißheimer S, Stangl S, Diederichs C, Wergin M, Bley CR, Haller B, Multhoff G. Hsp70 serum levels in pet dogs-a potential diagnostic biomarker for spontaneous round cell tumors. Cell Stress Chaperones 24(5): 969-978, doi: 10.1007/s12192-019-01024-9, 2019.
  76. Kühnel A, Schilling D, Combs SE, Haller B, Schwab M, Multhoff G. Radiosensitization of HSF-1 knockdown lung cancer cells by low concentrations of Hsp90 inhibitor NVP-AUY922. Cells 8(10): 166. doi: 10.3390/cells8101166, 2019.
  77. Pockley AG, Vaupel P, Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther 20(1):23-33, doi: 10.1080/14712598.2020.1688298, 2020.
  78. Issels RD, Lindner LH, Bergwelt-Baildon M, Lang P, Rischpler C, Diem H, Mosetter B, Eckl J, Schendel DJ, Salat C, Stötzer O, Burdach S, Luettichau-Teichert I, Handgretinger R, Neumann J, Kirchner T, Steiger K, Boxberg M, Mansmann U, Multhoff G, Noessner E. Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report. Int J Hyperther 37(1): 55-65, 2020.
  79. Fellinger H, Stangl S, Schnelzer AH, Schwab M, Di Genio T, Pieper M, Werner C, Shevtsov M Haller B, Multhoff G. Time- and dose-dependent effects of ionizing irradiation on the membrane expression of Hsp70 on glioma cells. Cells 9(4): 912. doi: 10.3390/cells9040912, 2020.
  80. Shevtsov M, Balogi Z, Khachatryan W, Gao H, Vigh L, Multhoff G. Membrane-associated heat shock proteins in oncology: from basic research to new theranostic targets. Cells 9(5): E1263. doi: 10.3390/cells9051263, 2020.
  81. Kimm MA, Shevtsov M, Werner C, Sievert W, Zhiyuan W, Schoppe O, Menze BH, Rummeny EJ, Proska R, Bystrova O, Martynova M, Multhoff G, Stangl S. Gold nanoparticle mediated multi-modal CT imaging of Hsp70 membrane-positive tumors. Cancers 12(5): 1331, doi: 10.3390/cancers12051331, 2020.
  82. Klapproth AP, Shevtsov M, Stangl S, Li WB, Multhoff G. A new pharmacokinetic model describing the biodistribution of intravenously and intratumorally administered superparamagnetic iron oxide nanoparticles (SPIONs) in a GL26 l xenograft glioblastoma model. Int J Nanomedicine 15:4677-4689, doi: 102147/IJN.S254745, 2020.
  83. Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin Cancer Res, doi: 10.1158/1078-0432.CCR-20-1141, 2020.